Merck Loses Nasonex Patent Ruling Against Apotex in N.J.

Merck’s patent for the allergy drug Nasonex isn’t infringed by Apotex, a federal judge ruled. U.S. District Judge Peter Sheridan said today that Merck’s Schering unit had “failed to present credible evidence” of infringement, according to a court filing in Trenton, New Jersey. Sheridan also denied Apotex’s claim that Schering’s patent was invalid.
Bloomberg